At Upstream Bio we strive to reach the source of inflammation and conquer it. We are leveraging our diverse roots and the team’s substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones.
Location: United States, Massachusetts, Waltham
Employees: 11-50
Total raised: $400M
Founded date: 2021
Investors 6
| Date | Name | Website |
| 28.06.2022 | Omega Fund... | omegafunds... |
| - | Access Bio... | accessbio-... |
| 06.06.2022 | OrbiMed | orbimed.co... |
| - | TCG Crosso... | tcgcrossov... |
| 26.08.2022 | HBM Partne... | hbmpartner... |
| 04.10.2024 | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.06.2023 | Series B | $200M | - |
| 12.06.2022 | Series A | $200M | OrbiMed |
Mentions in press and media 5
| Date | Title | Description |
| 15.10.2024 | Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announc... |
| 08.06.2023 | Upstream Bio Announces $200M Series B Financing | - |
| 02.06.2022 | Upstream Bio Launches with $200M Series A | - |
| 02.06.2022 | Upstream Bio Raises $200M in Series A Financing | Upstream Bio, a Waltham, Mass.-based biotech company focused on inflammation, raised $200 million in Series A financing. The Series A round was led jointly by OrbiMed and Maruho Co., Ltd. with participation from Access Biotechnology, Dechen... |
| - | Upstream Bio | “At Upstream Bio we strive to reach the source of inflammation and conquer it. We are leveraging our diverse roots and the team’s substantial industry experience to develop therapies that ease the burden of inflammatory and allergic disease... |